Adaptive Methods: When and How Should They be Used in Clinical Trials?

被引:0
|
作者
Porcher, Raphael [2 ]
Lecocq, Brigitte [1 ]
Vray, Muriel [3 ]
机构
[1] Novartis Pharma SAS, Lab Novartis, F-92506 Rueil Malmaison, France
[2] Univ Paris Diderot, Hop St Louis, Paris, France
[3] Inst Pasteur, Paris, France
来源
THERAPIE | 2011年 / 66卷 / 04期
关键词
interim analysis; adaptative trial; experimental design; amendement; treatment selection; CONTINUAL REASSESSMENT METHOD; HYPOTHESES SELECTION; DRUG DEVELOPMENT; 2-STAGE DESIGNS; PHASE-I; INTERIM; SURVIVAL; POWER;
D O I
10.2515/therapie/2011044
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adaptive clinical trial designs are defined as designs that use data cumulated during trial to possibly modify certain aspects without compromising the validity and integrity of the said trial. Compared to more traditional trials, in theory, adaptive designs allow the same information to be generated but in a more efficient manner. The advantages and limits of this type of design together with the weight of the constraints, in particular of a logistic nature, that their use implies, differ depending on whether the trial is exploratory or confirmatory with a view to registration. One of the key elements ensuring trial integrity is the involvement of an independent committee to determine adaptations in terms of experimental design during the study. Adaptive methods for clinical trials are appealing and may be accepted by the relevant authorities. However, the constraints that they impose must be determined well in advance.
引用
收藏
页码:319 / 326
页数:8
相关论文
共 50 条
  • [41] Diagnostic thresholds in osteoporosis: How are they used in clinical trials?
    Hamdy R.C.
    Price D.M.
    Mottl M.M.
    Current Osteoporosis Reports, 2011, 9 (3) : 160 - 166
  • [42] How AI is being used to accelerate clinical trials
    Hutson, Matthew
    NATURE, 2024, 627 (8003) : S2 - S5
  • [43] How much should dialysis time be increased when catheters are used?
    Maduell, F.
    Vera, M.
    Arias, M.
    Fontsere, N.
    Blasco, M.
    Serra, N.
    Bergada, E.
    Cases, A.
    Campistol, J. M.
    NEFROLOGIA, 2008, 28 (06): : 633 - 636
  • [44] How and when should combination therapy be used? The role of an anchor drug
    Farr, M
    Bacon, PA
    BRITISH JOURNAL OF RHEUMATOLOGY, 1995, 34 : 100 - 103
  • [45] When and how should adjuvant radiation be used in early endometrial cancer?
    Alektiar, Kaled M.
    SEMINARS IN RADIATION ONCOLOGY, 2006, 16 (03) : 158 - 163
  • [46] When, for How Long and in Whom Should Medical Expulsive Therapy be Used?
    Monga, Manoj
    JOURNAL OF UROLOGY, 2014, 191 (03): : 581 - 581
  • [47] How effective is temozolomide for treating pituitary tumours and when should it be used?
    Carmel Halevy
    Benjamin C. Whitelaw
    Pituitary, 2017, 20 : 261 - 266
  • [48] When and how to include vulnerable subjects in clinical trials
    Wendler, David
    CLINICAL TRIALS, 2020, 17 (06) : 696 - 702
  • [49] Zelen design clinical trials: why, when, and how
    Simon, Gregory E.
    Shortreed, Susan M.
    DeBar, Lynn L.
    TRIALS, 2021, 22 (01)
  • [50] Zelen design clinical trials: why, when, and how
    Gregory E. Simon
    Susan M. Shortreed
    Lynn L. DeBar
    Trials, 22